Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 t-haNK, N-803, and Rituximab in Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma
NCT07477366Phase 2Not yet recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Cytokines & Interferons
01
Overview
A Phase 2 trial of CD19t-haNK, nogapendekin alfa inbakicept in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by ImmunityBio, Inc.. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
CD19t-haNKnogapendekin alfa inbakicept
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT07477366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477366.